Deucravacitinib Remains Safe, Effective Through Week 52 in Psoriatic Arthritis

(MedPage Today) -- At the American College of Rheumatology (ACR) virtual meeting, new data were presented on deucravacitinib (Sotyktu), a highly specific tyrosine kinase 2 ( TYK2) inhibitor that has been approved for patients with plaque psoriasis...